Terns Pharmaceuticals, Inc. Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

TERN

株式のランク #3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
株価
$52.95
最終同期: 2026-05-15
時価総額
$4.77B
変化(1日)
0.00%
変化(1年)
529.61%
国
US
取引 Terns Pharmaceuticals, Inc. (TERN)

カテゴリー

Healthcare
Terns Pharmaceuticals, Inc.(TERN)のEPS
December 2025 時点のEPS TTM: $-1.03
Terns Pharmaceuticals, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-1.03です。2023年末には、EPSは$-1.27で、2022年のEPS$-1.67と減少でした。
Terns Pharmaceuticals, Inc.のEPS履歴(2018から2026まで)
各年末時点のEPS
年 EPS 変化
2026 (TTM) $-1.03 -8.04%
2024 $-1.12 -11.81%
2023 $-1.27 -23.95%
2022 $-1.67 -15.66%
2021 $-1.98 22.98%
2020 $-1.61 -41.24%
2019 $-2.74 270.27%
2018 $-0.74 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差 国
$17.32 -1,781.55%
US
$-7.98 674.76%
US
$-5.29 413.59%
AU
- -
CH
$27.74 -2,793.20%
NL